Cannabis News
Authoritative coverage of the global cannabis industry — regulation, investment, markets and policy, reported for the people who run it.
Cannabis News · page 86
- Uncategorized
Leafwell Research: Anxiety Tops List for Young Medical Cannabis Patients in US
A comprehensive study conducted by Leafwell offers a deep dive into the medical cannabis usage patterns among individuals under the age of 21 in the United States, a demographic that has been largely under-researched.
- Uncategorized
Rescheduling Delay Sends Cannabis Stocks Into Tailspin
News that the US Drug Enforcement Administration (DEA) is set to host a public administrative hearing on cannabis rescheduling has immediately impacted cannabis stocks.
- Press releases
Dalgety Secures EU-GMP Certification and Upgraded Home Office License
Dalgety has become one of two leading medical cannabis cultivators in the UK to be granted a Home Office licence to supply in the UK alongside a full EU-GMP certification.
- Policy & Regulation
Czech Cannabis Bill Stalled as Political Battle Heats Up, But Hope Remains for Full Legalisation
The Czech Republic’s cannabis legalisation project remains stuck in political and legislative limbo, as the rumour mill surrounding its future moves into overdrive.
- Uncategorized
Dutchie and Last Prisoner Project Reach $2M Fundraising Goal with Leading Tech Platform Matching $1M in Donations to Help End Victimless Cannabis Criminalization
Dutchie, the technology platform powering cannabis commerce, and Last Prisoner Project (LPP), a nonprofit dedicated to undoing the harms of the failed war on drugs and releasing people who are imprisoned on cannabis charges, today announced that their goal of $2 million in donations has been achieved.
- Uncategorized
Cannabis Rescheduling Faces Delays as DEA Schedules Post-Election Hearing
Cannabis rescheduling will now likely be delayed until next year as the US Drug Enforcement Administration (DEA) confirmed its plans to hold a hearing on the proposal after the election.
- Uncategorized
Canadian Cannabis Sales Continue Turbulent Year With 2% Downturn in June
Canadian cannabis sales have continued their mixed performance through June 2024, seeing another dip in total sales, but some states are showing resilience.
- Opinion
Why the UK Needs to Fund Research on Medical Cannabis and ADHD
Written for Business of Cannabis by Iqra Arif MPharm at Wellford Medical Clinic Understanding ADHD Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder that impacts both children and adults.
- Uncategorized
New York’s Legal Cannabis Sales Pass $500m Mark as Crackdown on Illicit Market Continues
New York’s legal cannabis market has crossed the $500 million sales mark, a significant milestone attributed to intensified efforts to eliminate unlicensed sellers.
- Pharmaceutical
Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare
Advancing Pharmaceutical Innovation: Brains Bioceutical’s CEP Certification will Streamline Cannabinoid Drug Development, Inspired by Jazz Pharmaceuticals’ CBD-Based Epilepsy Drug and 2024 $1.4 Billion Revenue Projection Brains Bioceutical Corp.
- Medical
Ukraine Legalises Medical Cannabis, But PTSD Currently Omitted From Official List of Conditions
Last week, Ukraine’s law officially legalising medical cannabis came into effect, eight months after initially being passed.
- Markets & Stocks
Synbiotic Hails Sales Growth Post-CanG, Stenocare Halves Sales Forecast for 2024, & Argent Bio. Delists From ASX
Synbiotic [stock_market_widget type=”chart” template=”line” assets=”SBX.F” range=”1mo” interval=”1d” price_field=”close” border_width=”3″ tension=”0.5″ line_color=”#5679FF” range_selector=”true” axes=”true” cursor=”true” api=”yahoo-finance”] German cannabis group Synbiotic published an update on its eclectic portfolio of businesses this week, seeing sales rise across the board following the passage of CanG.
